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ABSTRACT 
E. coli contains five different tRNAs which recognize the six leucine 
codons. These tRNAs are all recognized by the single leucyl-tRNA 
synthetase (LeuRS). We have used in vitro and in vivo methods to 
determine the set of identity elements which distinguish the set of leucine 
tRNAs from all other tRNAs allowing the faithful translation of the leucine 
codons. 
An identity swap experiment has been used to determine which of the 
nucleotides conserved in all leucine tRNAs are identity elements. In this 
experiment the identity of an amber suppressor tRNASer was changed 
completely to leucine. This experiment was effective because the 
anticodons in tRNA Ser and tRNA Leu are not recognized by their 
respective synthetases and consequently in both cases tRNAs containing the 
CUA anticodon required in amber suppressors are fully active. 
In its minimal form the Ser-Leu swap required six changes, five of 
which altered the tertiary structure of the tRNA: the G 15-C48 tertiary 
"Levitt base-pair" in tRNA Ser was changed to Al5-U48 found in all 
leucine tRNAs; it was necessary to insert one nucleotide and to delete one 
nucleotide so as to position the conserved D-loop Gl8, Gl9 nucleotides as 
they are in all leucine tRNAs; a base was inserted at position 47n between 
the base-paired extra stem and the T-stem to achieve a configuration found 
in all leucine tRNAs; in addition it was necessary to change the G73 
"discriminator" base in tRNA Ser to A73, found in all leucine tRNAs. This 
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minimally altered tRNA Ser inserted exclusively leucine as an amber 
suppressor and it was an excellent in vitro substrate for LeuRS. 
Both tRNA Ser and tRNALeu are type II tRNAs containing large base-
paired extra stem loops. In the case of tRNA Ser the extra stem loop is a 
crucial identity element but for tRNA Leu earlier in vitro and in vivo 
experiments had indicated that it is not an identity element. To investigate 
the role of tRNA tertiary structure in leucine identity we carried out a 
parallel swap experiment in which the glutamine identity of the amber 
suppressor tRNA Ser~ (in which the type II extra stem loop had been 
replaced by a consensus type I loop) was converted to leucine. This "type 
I" swap experiment was also successful both in vivo and in vitro. 
Interesting differences in the role of conserved leucine base-pairs in the 
acceptor stems of leucine tRNAs were observed in the two experiments. In 
the type II swap the conserved acceptor stem bases were not important. In 
the type I swap their absence had a large effect both in vivo and in vitro. 
This result indicates that the presence of the extra stem loop in leucine 
tRNAs has an effect on the tertiary structure of the tRNA. When this 
structure is altered conserved nucleotides, unimportant in its presence, take 
on an important role. Possible reasons for this effect are discussed. 
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The Specificity Problem in Protein Synthesis 
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Introduction 
The specific interactions between RNA and protein play a critical 
role in many cellular processes (1 ). One of the most interesting and 
important of these is the specific interaction between aminoacyl RNA 
synthetases (aaRS) and tRNA. The aaRS must recognize its cognate 
tRNA, and this interaction determines which amino acid is activated for 
protein synthesis. Once the tRNA is charged with an amino acid, the fate 
of that amino acid in protein synthesis is determined by anticodon-codon 
interactions in the ribosome. So an error in the aaRS recognition step 
results in the incorporation of the wrong amino acid (2) . 
The performance required of an aaRS is a difficult one. All 
tRNAs are similar at the level of primary, secondary, and tertiary 
structure. About 20% of the nucleotides are invariant, and in some cases 
are involved in hydrogen bonds that stabilize the tertiary structure. The 
common tRNA structure is required because all tRNAs must interact 
with the ribosome, with elongation factors and with common RNA 
processing and modification enzymes. However, there must exist some 
distinguishing features within each set of cognate tRNAs which mediate 
specific interaction with the corresponding aaRS. InE. coli, there are 
about 45 tRNA species and 20 aaRS in E.coli (3), so of the 900 possible 
interactions between tRNAs and synthetases, only 45 are actually correct, 
5% of the total. The recognition problem is further complicated by a 
need for some flexibility in tRNA-synthetase recognition. Because of 
degeneracy in the genetic code, more than one isoacceptor tRNA must 
usually be recognized by a single synthetase. Thus, there must exist 
unique elements common to isoacceptor tRNAs recognized by the 
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cognate synthetase and not recognized by the other 19 aaRS. The cell 
has evolved to perform this task remarkably well. The error rate in 
protein synthesis is about l0-4 per step (4). 
What features of the three-dimensional tRNA molecule confer 
aaRS specificity? Because of the complexities of RNA structure, 
recognition can take place not only by direct base interactions, but also 
by contacts with the sugar-phosphate backbone. Additionally, the 
protein may recognize idiosyncratic features of the overall shape of the 
tRNA. There are two types of recognition elements: positive elements, 
which directly interact with the cognate aaRS or position other elements, 
and negative elements, which discourage interactions with non-cognate 
aaRS. These positive and negative elements for any isoacceptor group 
make up its identity set, and the subset of only the positive elements 
make up its recognition set. As discussed below, positive recognition 
elements can be determined by in vitro and in vivo experiments while 
negative elements can in general only be determined in vivo in the 
context of the competition of the 20 aaRS for a particular tRNA. 
In order to understand the identity problem in protein synthesis, a 
careful examination of each player in the process is necessary. In the 
next section I will review our current understanding of the sequence and 
structure of both the tRNA and the synthetases. 
Transfer RNA Structure 
The primary sequence information of tRNA is conveniently 
displayed in a standard RNA cloverleaf (5) (figure 1) illustrating the 
Watson-Crick base pairing between complementary sequences forming 
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the secondary structure of the tRNA. Each tRNA contains four helical 
"arms." The D-arm contains 3 or 4 base pairs in the stem and a loop 
which varies in length from 7 to 10 bases. The T-arm and the anticodon 
arm contain a 5 base pair stem and a loop of 7 bases. The nucleotides at 
positions 34, 35, and 36 are the anticodon. The acceptor aim consists of 
a stem of 7 base pairs (except tRNAHis which has an extra base pair) and 
an unpaired sequence of four bases whose 2' or 3 '-OH group is 
aminoacylated. Distinctive features of the single-stranded sequence ai·e 
the terminal CCA, universally invai·iant among all the tRNAs, and the 
base at position 73, the discriminator nucleotide (6). 
The crystal structure of yeast tRNAPhe (7, 8). (figure 2) reveals 
that most of these invariant nucleotides are involved in hydrogen 
bonding interactions which are required to maintain the tertiary 
structure. The hypothesis is supported by the crystallographic data for 
yeast tRNAAsp (9, 10), E.coli tRNA Gin (11), tRNAMet(l 2),and 
T.thermophilus tRNA Ser (13). In all of these the crystal structures the 
tRNA forms a similar L shaped structure created by the intersection of 
two double helices whose axes subtend an internal angle of about 900 
(figure 2 (10)). The T-arm and the acceptor arm form one coaxial 
helix; the D-ai·m and the anticodon arm f01m the other one. The double 
helices intersect in a central domain which contains the T-loop and the 
D-loop. Tertiary interactions in the single stranded D and T-loops 
between the invariant bases (G l 8-Y55, G 19-C56, A9-A23, T54-A58, 
U8-A14), and the semi invai·iant bases [(positions 15-48 (the Levitt base 
pair), positions 9-23-12, and positions 13-22-46 (not present in type II 
tRNA, because of the extra arm)] establish the central core and ai·e 
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responsible for its 3-dimensional folding shown on figure 2. A group of 
bases in this domain which differ among the different isoacceptors 
groups, form a variable pocket ((7, 8). In yeast tRNAPhe these are 
bases 16, 17, 20, 59 and 60. Because this region is variable and on the 
surface of the molecule it was suggested that the variable pocket could be 
important in aaRS recognition(8). Among the different tRNAs there is 
only slight variation within these sequence and structural constraints, and 
these variations are responsible for accurate tRNA synthetase 
recognition. The differences between tRNAs are in the sequence of their 
anticodons, the sequences of the base-paired arms and in the 
discriminator base, N73, in the length and sequence of the extra-arm, in 
the sequence and organization of the variable pocket and in the sequence 
of the bases in the D-loop. The a region (positions 16,17, and 17a) and 
the B region (positions 20, 20a, and 20b) of the D-loop, through tertiary 
interactions, determine the structure of the variable pocket so these bases 
can determine specificity by affecting tertiary structure. Thus the 
recognition of tRNA could be via one, or more likely a combination, of 
these distinctive features. 
Aminoacylation takes place at one end of the L-shaped molecule, 
and the anticodon loop is at the other end 80 A away in the tertiary 
structure. This means that recognition of the anticodon would require 
that the aaRS be at least this length. As we shall see the aaRS are, in fact, 
elongated, multi-domain proteins which often do, in recognizing the 
tRNA, span its entire length. 
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Aminoacyl tRNA Synthetase Structure 
The aaRS constitute a family of enzymes that vary in size and 
quaternary structure, and yet are responsible for the same function, the 
recognition and ATP-dependent acylation of tRNA. This occurs in two 
steps. In the first step the aaRS binds ATP and the amino acid and f01ms 
a mixed anhydride between the amino acid and AMP, aminoacyl AMP, 
with the release of pyrophosphate. This reaction requires magnesium 
ions. This step can typically be carried out in the absence of tRNA, with 
the exception of GlnRS, GluRS, and ArgRS where the aaRS need to bind 
the tRNA before being able to bind ATP (14 ). In the second step the 
tRNA is aminoacylated at its 3' terminus, and released from the enzyme. 
On the basis of sequence similarities, the aaRS can be divided into 
two classes (table 1) (15-17). This classification is also correlated with 
the ability of the aaRS to attach the amino acid to either the 2'-hydroxyl 
group of ribose (class I) or the 3'-hydroxyl group (class II, with the 
exception of PheRS). The crystal structures of 11 different aminoacyl-
tRNA synthetases with and without their substrates have been solved(l 8): 
MetRS (19), TyrRS (20) , GluRS (21), TrpRS (22), and GlnRS (23) in 
class I, SerRS (13), AspRS (9), LysRS (24), HisRS (25), GlyRS (26), and 
PheRS (27) in class II. Class I aaRS contain an active site that is a 
Rossman nucleotide binding fold formed by a B-sheet of five parallel 
strands, surrounded by ex helices. Class II aaRS contain an active site 
domain formed by a B-sheet of six antiparallel strands , in contact with 
two ex helices. Two class II co-crystal structures and one class I have 
been solved. These are E.coli GlnRS-tRNA Gln (11) ,yeast AspRS-
tRNAAsp (9), and T.theromphileusSerRS tRNASer (13, 28). The 
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structural differences in the active site correlate with the direction from 
which the aaRS approaches the tRNA molecule. Class I aaRS approach 
the tRNA from the D-loop side, establishing contacts with the anticodon 
and the minor groove of the acceptor stem. Thus the single-stranded 
CCA 3' must make a sharp turn in order to enter the active site. Class II 
aaRS approach the tRNA from the variable arm side and also (with the 
exception of AlaRS and SerRS) interact with the anticodon. However, 
they contact the major groove of the acceptor stem, thus allowing the 
CCA 3' to fit into the active site without any distortion of the helical 
conformation. The co-crystal stiuctures also illustrate that the enzymes 
are organized in "modules" or domains. In general each domain binds a 
characteristic recognition site in the tRNA(29). 
A Perspective on tRNA-Synthetase Recognition 
Elucidating the mechanism of tRNA-synthetase recognition 
requires a combination of approaches. Our present understanding of the 
molecular mechanisms responsible for the recognition of tRNAs by their 
cognate aaRS is essentially based on three sources of information: a) the 
characterization of tRNA identity determinants b) the structural results 
of crystallographic investigations and c) physical chemical studies of the 
interactions between tRNA and aaRS in solution .. 
The Characterization of tRNA Identity Determinants 
Two main experimental approaches have been used to determine 
the recognition elements that distinguish one set of tRNAs from all 
others. Each method has its advantages and constraints. Although 
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different kinds of information are derived from the approaches, the 
results from the two approaches often agree though, of course, negative 
identity elements cannot be explained by the results from studies of 
cognate pair interactions . 
The in vivo Approach 
This method is based upon previous work that has been reviewed 
in detail elsewhere (30). Transfer RNA suppressors for the amber 
codon were used three decades ago to study the altered specificity of 
genetically isolated E.coli tRNATyr amber suppressor mutants. Altered 
specificity with single base mutants was observed and it was exclusively a 
change to glutamine identity(31 , 32) . Because it was technically 
unfeasible to genetically isolate multiple mutations at will, additional 
identity changes could not be identified at the time. 
However advances in oligonucleotide synthesis made it possible to 
construct genes of variant tRNA suppressors by annealing and ligating 
different oligonucleotides and cloning them into a plasmid under the 
control of an E.coli promoter to be constitutively transcribed (33, 34). 
The biological functionality of the mutant is established by analyzing the 
efficiency with which the tRNA was able to suppress an amber mutation 
in the lacZ gene when the tRNA gene is under the control of the E. coli 
lpp promoter. This is called an efficiency assay (35). The amino acid 
identity of the tRNA suppressor is determined by sequencing the protein 
product of a reporter gene containing an amber mutation . Our 
laboratory has used an amber mutation at position 10 in the E.coli 
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dihydrofolate reductase gene for this purpose. The amino acid residue 
of the suppressed DHFR at position 10, sometimes a single amino acid, 
sometimes a mixture is determined by the identity of the amber 
suppressor gene that is being examined. This assay is an "identity assay" 
(36). Both amber mutations in the two reporter genes are engineered at 
positions that are away from the catalytic site of the protein, and 
therefore any amino acid can be accepted without altering the 
functionality of the mutated protein. These studies have allowed the 
identification of the minimal number of base changes needed to cause 
one tRNA species to be selectively aminoacylated by a non-cognate 
synthetase. This is called an "identity swap" experiment. The set of 
these minimal changes has been defined as the identity set. The identity 
set includes the positive elements for one aaRS and the negative elements 
for the remaining 19. 
Unfortunately, it is difficult to directly correlate the results of the 
efficiency and the identity assays with in vitro aminoacylation results 
using pure tRNA and aaRS. The efficiency assay is not only the result of 
how well a tRNA suppressor is aminoacylated, but also how well it is 
processed and modified, and how well it interacts with the translational 
apparatus. The specificity assay reflects the outcome of the competition 
for aminoacylation of the tRNA by all 20 aaRS. 
The in vitro Approach 
The development of an in vitro transcription method by which 
transcripts from synthetic tRNA genes could be obtained has allowed the 
creation of any desired tRNA variant and its recovery (as an unmodified 
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transcript) in large quantities (37). The fact that these transcripts are 
purified in denaturing conditions and that they do not have secondary 
modifications, does not seem to prevent their correct refolding into the 
active conformation. These substrates allow quantitative comparisons to 
be made of the effects of base changes at specific recognition sites by 
purified aaRS , within the range of feasible enzyme and substrate 
concentrations. 
Applying both the in vitro approach, determining the recognition 
set, and the in vivo approach to determining the identity set elucidates 
which specific interactions between a tRNA and aaRS are crucial. A lot 
of progress in elucidating the tRNA identity rules has been made in 
recent years (30, 38-43). We now have information about how all 20 
sets of E. coli tRNA are recognized. The recognition elements for the 
aaRS have been located in the anticodon, the acceptor stem and the 
discriminator base at position 73, and the central core. Often the 
identity of a particular tRNA is determined by elements in more than 
one of these regions. 
Recognition of the Anticodon 
The anticodon is a single-stranded region with bases available for 
interaction. Transfer RNAs from different isoacceptor groups have 
different anticodon sequences as dictated by the genetic code and the 
"wobble rules" (44). Therefore it is logical that the anticodon is one of 
the recognized features (45-51). 
The Abelson laboratory in collaboration with the laboratory of 
Jeffrey Miller at UCLA undertook a project to synthetically create a 
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complete set of amber suppressors (33, 34) As it turned out all amber 
suppressors could not be made because the CUA anticodon required to 
recognize the UAG amber codon was not compatible with recognition by 
some aaRS. Substitution of the original anticodon with the amber 
suppressor anti codon in 20 isoacceptor groups of tRN As results in an 
identity change for 9 isoacceptor groups (see table 2). Most of them are 
misacylated with glutamine or lysine, indicating that a U at position 35 is 
a positive element for GlnRS and LysRS and subsequent research 
confirmed this for GlnRS (52, 53) and for LysRS (54). In the case of the 
isoacceptor groups that retain the original identity, there are 3 possible 
explanations: a) the cognate aaRS does not recognize the anticodon; b) 
there are sequence homologies between the original anticodon and CUA; 
or c) there are strong negative elements for GlnRS and LysRS. Transfer 
RNAAla, tRNA Ser, and tRNALeu have been characterized in vitro and 
have been shown to lack detectable anticodon-dependent aminoacylation 
(55-57). In these cases, the wild-type anticodons might actually function 
as negative elements for the other aaRS. In the case of the amber 
suppressor tRNA Cys (58), tRNAPhe (59), and tRNA Gln (53) it has been 
shown that even if the in vivo identity is retained, the aminoacylation of 
the tRNA by the cognate aaRS is decreased with respect to the wild-type 
tRNA. 
Mutation of the anticodon results in significant reduction of in 
vitro aminoacylation for 17 of the isoacceptor groups (table 3). As 
expected from the in vivo data, the effects vary between the different 
groups. Single nucleotide substitution has a major effect in some cases 
(table 3), in other cases, however, more than one nucleotide must be 
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changed in order to see an effect (table 3), implying that the sum of the 
combined contribution of the three nucelotides of the anticodon is 
important for recognition. 
The fact that the transcribed tRNAs do not contain the secondary 
modifications otherwise present in the cell illustrates the necessity of 
certain modified bases for the c01Tect interaction with the aaRS. 
Secondary modifications in the anticodon of tRNAile (lysidine at 
position 34) (60, 61) and tRNA Glu ( 2-thiouridine at position 34) (62) 
are positive elements directly contacted by the cognate aaRS. A single 
methyl group modification of G37 is a negative element preventing 
mischarging of tRNAAsp (63) by yeast ArgRS, in vitro T7 transcripts of 
wild-type tRNAArg and tRNAAsp are aminoacylated with equal 
efficiency. 
The Acceptor Arm 
The aaRS generally have at least two major domains which interact 
with the tRNA. The catalytic domain which comprises the interclass 
conserved active site, interacts with the acceptor arm of the tRNA. The 
other domain contacts the anticodon and its coaxial helix. Even though 
the majority of aaRS interact with the anticodon, introducing mutations 
in the acceptor stem and the discriminator base of these tRNAs often 
affects aminoacylation both in vivo and in vitro (49). Several tRNAs 
containing mutations in the anticodon are still charged with the original 
amino acid or with a mixture of amino acids, suggesting that there are 
additional recognition elements outside of the anticodon of these tRNAs. 
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"Minihelix" constructs consisting of the acceptor stem and the T-
stem and loop and "microhelices" (comprised of only the acceptor aim) 
derived from the sequences of the cognate tRNAs can be aminoacylated 
in an anticodon independent manner by the HisRS, AlaRs, GlyRS (64), 
SerRS (65), MetRS (66), GlnRS (38), ValRS (67), AspRS (68), and 
IleRS (68). The role of the acceptor stem in aminoacylation specificity 
is sequence-specific and depends on the accessibility of the base pairs of 
the A-helix. The acceptor stem fo1ms an A-RNA helix with a deep and 
narrow major groove, inacessible, and a wide and shallow minor 
groove, easily accessible (69). According to the model, deduced from 
the three co-crystal strnctures, the class I aaRS should interact with the 
minor groove, and the class II aaRS with the major groove. 
The class I aaRS, GlnRS contacts tRNA Gln in the minor groove, 
and in this specific case the interaction is also made possible by the 
melting of the base pair at the end of the helix (see the discussion of the 
GlnRS-tRNA Gin co-crystal below) (11). 
Class II aaRS contact their cognate tRNAs in the major groove, 
where base specific interactions are not available except for the base 
pairs close to the end of the acceptor stem helix (70), and they solve this 
accessibility problem in different ways. 
AspRS makes specific base contacts only with the single stranded 
discriminator and base pair Al-U72 and by forming hydrogen bonds 
with the phosphate backbone of the acceptor stem base pairs (9). 
SerRS interacts with the first two base pairs at the 3'-end of the 
acceptor stem helix, and makes specific contacts with U68 and C69 by 
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forming hydrophobic interactions with the ring of residue Phe262, 
which is perpendicular with respect to the base pairs(28, 65). 
AlaRS interacts with the G3-U70 wobble pair G2-C71, and also 
A73 in the acceptor stem of its cognate tRNA (71, 72). Introducing G3-
U70 into tRNAPhe, or into RNA mini and micro helices causes these 
RNAs to be aminoacylated by AlaRS (57, 73, 74)., and substitution of 
G3 with the base analog inosine (identical to guanosine except for a keto 
group replacing the 2 -amino group of G) affects aminoacylation by 
AlaRS (75). The G3-U70 base pair presents an exocyclic 2-amino group 
in the minor groove that is not involved in hydrogen bonding with the 
complementary base. Thus this specific interaction takes place on the 
opposite side of the helix than what is expected for class II synthetases. 
Crosslinking studies have shown that an insertion of 76 amino acids 
residues in the catalytic domain makes contact with the exocyclic 2-
amino group in G3-U70. This contact is postulated to occur via an 
extension of the protein in this region which reaches around the helix to 
contact the minor groove (76). 
Central Core 
The tertiary interactions between the single stranded D and T-loop 
invariant nucleotides, forming the central core; the semi invariant 
nucleotides, forming the Levitt base pair; the non conserved nucleotides 
in the D-loop, forming the variable pocket; and the D-stem, forming the 
central part of the molecule are all important for the L-shape structure 
and may be involved in direct interactions with the aaRS. 
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Unfortunately, the role of these elements is not always so evident, 
because of the conformational changes that can be introduced by 
mutations in these positions. Another misleading factor as far as 
recognition goes can be a masking effect due to other recognition sites 
located elsewhere in the tRNA. There are already several examples of 
aaRS involved in direct recognition of some of these features. 
The Asp RS specifically contacts G 1 O-U25 in the stem of the D-aim 
of tRNAAsp (9), but the coITect st1ucture of the tRNAAsp is required 
for the presentation of this feature and efficient aminoacylation. 
Mutations in positions involved in tertimy interactions in the D-loop, not 
directly contacted by the AspRS as shown in the crystal st1ucture, alter 
the presentation of this base pair resulting in a decreased efficiency of 
aminoacylation and a vai·iation in the chemical protection pattern(77). 
Yeast PheRS recognizes G20 in the D-loop and is more sensitive to 
the correct folding of the molecule than to the sequence that is involved 
in forming the tertiary interactions. The central core of the tRNA has 
been studied in detail by systematically mutating nucleotides, invai·iant 
and semi invai·iant, involved in tertiai·y interactions, as shown on the 
crystal structure. Substitution of tertiai·y interactions with the 
c01Tesponding interactions typical of other tRNA results in substrates 
that ai·e efficiently aminoacylated. Furthermore, the structural specific 
lead cleavage pattern is the same as the wild type. It is only when the 
tertiai·y structure is changed, destroying the tertiary interactions, that the 
aminoacy lation is affected . 
While it was known that E.colitRNAPhe G20 was an important 
recognition site, it was also thought that nucleotides G 1 O-C25-A-26, and 
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G44-U45 fonning tertiary interactions in the central core were 
important recognition sites for the E.coli PheRS. They appeared to be 
positive elements of the identity set of tRNAPhe in vivo (71). Mutations 
at these positions caused a decrease in aminoacylation in in vitro studies, 
although the structure specific lead cleavage proved the mutated tRNA to 
have a correct structure(59 ), lending support for the notion that 
sequence specific interactions were crucial. Surprisingly, a variety of 
sequences were tolerable at these positions. In vitro selection of tRNA 
molecules from a tRNAPhe library randomized at these positions 
demonstrated the possibility of alternative tertiary interactions. The 
possibility of a direct contact is therefore excluded, and the role played 
by these interactions and the newly selected sequences is to direct the 
correct structure of the tRNA (78). 
Of course in some cases, tertiary interactions in the central core 
play an important role in the recognition. For example, for tRNA Cys. 
Substitution of the Levitt base pair sequence G l 5-G48, unique to 
tRNA Cys, results in tRNAs with unaltered structure, but affects 
aminoacylation (58, 79, 80). 
Crystallographic Investigations and Solution Studies 
Three tRNA-synthetase co-crystal structures have been solved by 
X-ray diffraction. These structures provide an excellent correlation 
with the available data from the in vivo and in vitro studies. 
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The tRNAGln I GlnRS complex 
The refined crystal structure of E. coli glutaminyl tRNA 
synthetase complexed with tRNA Gin (figure 3) was the first aaRS-tRNA 
structure solved (11). The diffraction studies show that the catalytic site 
of class I synthetases form a Rossman-like ATP-binding motif , and shed 
light on how class I aaRS approach the tRNA (81, 82). There are many 
interactions taking place between the tRNA and the aaRS, some are base 
specific; others are interactions with the phosphate backbone that require 
the presence of a specific base for structural reasons. The structure of 
the anticodon loop of the tRNA, interacting with GlnRS goes through an 
evident structural reaITangement, especially if compared with the crystal 
structure of tRNAPhe(7, 8). The anticodon loop appears to be extended 
by the presence of two stacked, non-Watson-Crick base pairs in the 
anticodon stem. This results in the protrusion of the three unpaired 
anticodon nucleotides, essential sites for GlnRS recognition. These bases 
can form several hydrogen bonds to complementary pockets in the 
protein. U35, and G36 are directly in contact with the GlnRS as has 
been demonstrated by extensive in vitro studies (23, 83). 
The acceptor stem also goes through conformational changes on 
GlnRS binding. The base-pair Ul-A 72 is disrupted to allow the single 
stranded 3'-end to point towards the catalytic site and fit into a deep 
pocket in the GlnRS. Substitution of the more energetically stable base 
pair G-C at this position resulted in a decrease in aminoacylation by the 
GlnRS in vitro (84). The role played by this base pair could not have 
been deduced without the structure. This conformational change is also 
stabilized by the stacking of A 72 and G73. The discriminator base, G73, 
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positions the 3' end by fonning a hydrogen bond between its 2-amino 
group and the phosphate linking C71 and A 72. This RNA-RNA 
interaction explains the requirement for a G at 73. Thus G73 is an 
identity element by virtue of its affect on RNA structure and not via its 
specific interaction with the protein, an important precedent to keep in 
mind when interpreting the function of identity elements. GlnRS, a class 
I synthetase, interacts with the minor groove of the acceptor stem 
contacting the exocyclic 2-amino group of bases G2 and G3,. This 
interaction has been confirmed by in vivo (85) and in vitro (53) 
studies, and is consistent with the sequences of glutamine amber 
suppressors selected in vivo from a tRNA library randomized at the 
acceptor stem (85). The fact that GlnRS is capable of aminoacylating 
minihelix substrates is also a further testimony to the important role 
played in specificity by the acceptor arm (38) 
Since the solutioi:i of the tRNAPhe structure (7, 8) it has been 
apparent that the anticodon is a long ways away from the 
aminoacylation site. Whether, and if so how, the anticodon and the 
acceptor stem "comunicate" between each other once they interact with 
the aaRS is still an open question. In an attempt to test the possibility of 
a functional communication between the two sites, the effect on GlnRS 
aminoacylation of acceptor arm minihelices by anticodon minihelices 
was tested. There was no effect unless the minihelices were in cis, 
although it was a very promising fact that the anticodon minihelices 
were shown to inhibit the aminoacylation of full length tRNA (38). 
tRNA Asp I Asp RS complex 
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The refinement of the crystal structure of the complex formed by 
yeast AspRS and tRNAAsp (9, 86) (figure 4) has provided an 
understanding of the recognition of tRNA by class II aaRS. AspRS 
exhibits the class II characteristic catalytic site domain that have been 
described in the aaRS section of this review. It contains one catalytic site 
with a tRNA molecule bound in each of the two identical subunits. In 
the comparison with the previously solved structure of GlnRS it is 
obvious that AspRS approaches the tRNA molecule from the opposite 
side-from the variable loop side and interacts with the major groove of 
the acceptor stem. The X-ray diffraction studies show that three 
"modules" of AspRS are in contact with the recognition sites of 
tRNA Asp. As in the case of tRNA Gln, tRNAAsp goes through 
conformational changes upon binding its cognate aaRS. The novelty in 
the case of tRNA Asp is that the structure of tRNA Asp alone has been 
solved (10). This allows comparison between the tRNA structure 
before and after binding to AspRS. The anticodon loop, as in tRNA Gln, 
undergoes a conformational change. The three nucleotides G34, U35, 
and C36 in the anticodon directly interact with the protein. The base 
G 10 is also contacted in the D-arm of the tRNA. Contrary to what is 
seen in tRNA Gln, the acceptor stem does not go through major 
conformational changes and only the discriminator base G73 and base 
Ul-A 72 are specifically contacted by AspRS. The other contacts with 
the protein are with the phosphate backbone of the single-stranded 3'-end 
four nucleotides of the acceptor arm. Because of the way it approaches 
the tRNA, the AspRS contacts the major groove of the acceptor stem 
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explaining why a conformational change in the 3'-CCA is not necessary 
for the terminal A to fit into the catalytic site. 
The importance of these recognition sites has been confinned by 
in vitro aminoacylation studies of T7-transcribed tRNAAsp mutants and 
also by chemical protection studies of iodine cleavage of 
phosphorothioate-substituted transcripts in the presence or the absence of 
AspRS. Introducing mutations at the recognition sites G73, G 1 O-U25, 
G34, U35, and C36 (with the exception being base pair Ul-A72 where 
changing it to G-C does not alter the aminoacylation) leads to a decrease 
in aminoacylation and also results in the protection pattern varying only 
in the position mutated. Interestingly, introducing these recognition sites 
for AspRS into tRNAPhe, not only transforms it into a substrate for 
AspRS aminoacylation but when the tRNA is tested for chemical 
protection gives the same protection pattern of wild-type tRNAASP(87) 
(88) . RNA mini and micro helices of the acceptor stem of yeast 
tRNAAsp are aminoacylated by the AspRS. Introducing changes in any 
of the acceptor stem positions does not affect the aminoacylation of the 
helix; only changing position G73 results in a loss of aminoacylation 
activity. The AspRS is insensitive to the acceptor stem sequence, only 
contacting the phosphate backbone. The fact that a minimal substrate 
consisting of only a tetra loop, three bases pairs, and the G73 is by the 
AspRS confi1m this (68). 
tRNASer I SerRS complex 
The most recently solved crystal strncture isT. thermophilus seryl-
tRNA synthetase with tRNASer(l3) (figure 5). The synthetase is a 
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dimer but only one tRNA molecule is bound in the complex. Most class 
II aaRS are dimers and thus have two catalytic sites, one for each 
subunit, but the way in which the dimer binds tRNA in SerRS is 
different from that in AspRS. tRNASer interacts with both subunits; 
tRNAAsp with only one. SerRS, a class II synthetase like AspRS, 
recognizes the major groove of the acceptor stem, making base specific 
contacts with the base pairs Gl-C72, G2-C71, G4-C69, and A5-U68 on 
one subunit, and with G47a-C47m in the extra arm and G19 in the D-
loop of tRNASer on the other subunit. The interaction of SerRS with 
the extra arm of the tRNA is peculiar to this system, and takes place via 
a striking protein structural domain formed by an antiparallel coiled-
coil. Position G 19 not in direct contact with the SerRS in the co-crystal 
is fundamental importance for the correct positioning of the extra-arm. 
Another peculiarity about this system is that SerSR is not involved in 
interactions with the anticodon of the tRNA. The refined structure of 
the SerRS alone(89), enables us to compare the confomational changes 
that are introduced into the protein upon tRNA binding (28) .. The 
GlnRS coil-coil domain goes through a confonnational change upon 
binding to the extra aim of the tRNA. The binding of the tRNA extra 
arm is a necessary first recognition step for efficient aminoacylation to 
take place in the catalytic site, where residues bound to the aminoacyl-
AMP by changing orientation alter the order of the structure. 
The different arms of E.coli tRNA Ser have been tested for their 
role in recognition by examination of the effects of systematic deletions 
on in vitro aminoacylation by SerRS (55). The removal of the anticodon 
arm resulted in a tRNA with kinetics parameters identical to that of wild 
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type, supporting the notion that the anticodon is not involved in any 
interaction. The removal of the extra arm and its replacement with a 
typical type I tRNA loop consensus resulted to serine identity loss in in 
vivo(90), and a substantial decrease in aminoacylation by the SerRS in 
vitro (55) . Phosphorothioate footprinting experiments also indicate 
direct contacts with nucleotides in the extra-aim and also the acceptor 
stem (91). Experiments in this thesis also show how c1ucial the 
orientation of the extra mm is for correct recognition by SerRS. 
An acceptor mm sequence in a minihelix substrate is 
aminoacylated by SerRS, allowing a study of the contribution of acceptor 
stem base pairs to recognition otherwise not immediately evident in full 
length tRNA Ser. The general picture of bases recognized in the acceptor 
stem was more detailed than that obtained from the initial crystal 
structure because this region was not resolved due to local disorder, in 
fact the interaction between tRNASer and SerRS is not only influenced 
by contacts with bases 4-69 and 5-68, but is also influenced by the base 
pair sequence at position 1-72, 2-71, and 3-70 (65). The high resolution 
structure studies confi1med these results and elucidated a novel 
interaction taking place between the ring of Phe262 residue and the rings 
of the bases at position bases U68 and U69, and the function of A3-U70 
necessai·y for the correct interaction with the recognition site base 
pairs(28). 
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Figure 2. Yeast tRNAPhe secondary structure. The invariant 
nucleotides involved in tertiary structure are indicated. 
Tertiary structure of type I tRNA (bottom left) . 
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Figure 3. E.coli tRNA Gln complexed with GlnRS (11). 
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Figure 4. Yeast tRNAAsp complexed with AspRS (9). 
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Figure 5. T.thermophilus tRNASer complexed with SerRS (13). 
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Table 1. Characteristics of aminoacyl-tRNA synthetases. 
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Table 1. Aminoacyl-tRNA Synthetases 
aaRS Class Oligomeric Site of a.a. No . Refs. 
Structure attachment catalytic 
sites 
Ala II ex4 3'-0H (92) 
Arg I ex 2'-0H (93) 
Asn II ex2 3'-0H (94) 
Asp II ex2 3'-0H 2 (9) 
Cys I ex 2'-0H (95) 
Gln I ex 2'-0H 1 (11) 
Glu I ex 2'-0H (96, 97) 
Gly II ex 2 ~ 2 3'-0H (26) 
His II ex2 3'-0H 2 (25, 26, 98 , 
99) 
Ile I ex 2'-0H 1 (100) 
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Table 1 cont. 
aaRS Class Oligomeric Site of a.a. No. Refs. 
Structure attachment catalytic 
sites 
Leu I a 2'-0H (101) 
Lys II a2 3'-0H (24) 
Met I a 2 2'-0H 2 (19) 
Phe II a2~2 2'-0H 2 (27) 
Pro II a2 3'-0H (102) 
Ser II a2 3'-0H 2 (13, 28) 
Thr II a 2 3'-0H (103) 
Trp I a 2 2'-0H 1 (104) 
Tyr I a 2 2'-0H 1 (20) 
Val I a 2'-0H 1 (105) 
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Amber Suppressor tRNA Genes 
(Classified by effect of a CUA upon aaRS Recognition) 
Class II Class III 
No affect upon charging GlnRS mischarging LysRS mischarging 
Ala2 GluA Arg 
GlyU Gly2 AspM 
Cys Ilel Ile2 
Phe fMet Met 








Table 3. Known recognition elements . 
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Table 3. Summary of Known Recognition Elements 
tRNA Anti codon Di scrim. Acceptor Stem D-stem X-Arm Refs. 
Base Loop Recog. 
Ala None A13 G2-C7!, Q3-U10 (106) 
Arg C3s A73 A20 (107, 
109) 
Asn G34U3sU36 Q73 (110, 
111) 




Cys G34C3sA36 U73 G14-G4s (119, 
122) 




Glu U34 G73 (49, 
62) 
Gly C3sC36 U73 G2-C11 , Q3-U10 (125, 
126) 
His U3s C73 G1-C73, U2-A7I, (64, 
G3-U10 127) 




Table 3 cont. 
tRNA Anti codon Di scrim. Acceptor Stem D-stem X-Arm Refs. 
Base Loop Recog. 
Leu None A73 G2-C7I, G3-U10 A1s-U4s No (56, 
130, 
131) 
Lys U34U3sU36 A73 (109) 
Met C34A3sU36 A73 G2-C7I , Q3-U10, (42, 
U4-A69 50) 
Phe G34A3sA36 None G20, Us9 , (37 , 
G10-C2s, 59, 71 , 
Az6, 78, 
G44, U4s 132, 
133) 
Pro G3sG36 A73 Ci-Gn G1s ,G4s (134, 
136) 
Ser None None G2-C11 , G4-C69, Yes (55 , 




Thr G3sU36 None (49) 
Trp C34C3sA36 Q73 (49, 
139) 
Tyr Q34U3sA36 A73 Yes (138) 
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Introduction 
The high degree of accuracy of the translation process is primarily 
the result of specific interactions between aminoacyl-tRNA synthetases 
(aaRS) and tRNA. Each of the 20 different aaRS recognizes its own set 
of cognate tRNAs and does not misacylate non-cognate tRNAs. All 
tRNAs are similar at the level of primary, secondary, and tertiary 
structure. About 20% of the nucleotides are invariant, and in some cases 
are involved in hydrogen bonds that stabilize the tertiary structure. The 
common tRNA st1ucture is required because all tRNAs must interact 
with the ribosome, with elongation factors and with common RNA 
processing and modification enzymes. However, there must exist some 
distinguishing features within each set of cognate tRNAs which mediate 
specific interaction with the corresponding aaRS. 
The results of studies aimed at defining the recognition properties 
of the various isoacceptor groups in E. coli have been summarized (30, 
39-43). The anticodon plays a fundamental role in recognition in 17 out 
of the 20 isoacceptors groups. Recognition elements may be present in 
the variable pocket, the acceptor stem, and in the extra arm of two of the 
three class II tRNAs. Generally, isoacceptor groups are recognized in at 
least two of these locations, in most cases the acceptor stem and the 
anticodon. 
The nucleotides which determine specificity in the interaction 
between tRNAs and their cognate aaRS have been identified by two 
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different methods. An in vivo method utilizes amber suppressor tRNAs 
and measures the efficiency and specificity of sequence variants of the 
amber suppressor. Efficiency, an indirect measurement of the activity 
of the tRNA in both the aminoacylation reaction and in protein synthesis, 
is measured by determining the extent to which a particular amber 
mutation, typically in the lacZ gene, is suppressed relative to the wild-
type suppressor (35). Specificity is measured by determining which 
amino acid(s) is inserted in the suppression of a particular amber 
mutation in a reporter gene. This is done by determining the amino acid 
sequence of the suppressed protein. In our laboratory we have routinely 
used an amber mutation in position 10 of E. coli dihydrofolate reductase 
for this purpose (36). Frequently, identity elements have been 
determined via an identity swap experiment. In this experiment an 
attempt is made to completely change the identity of one tRNA, e.g. 
tRNALeu in our first experiments, to another identity, tRNASer in that 
case (36). When that can be done, it perforce, results in the 
identification of important identity elements though not necessarily the 
complete set. The in vitro method for determining specificity involves 
the quantitative measurement of the kinetic parameters for the 
aminoacylation of variant tRNAs by a particular aaRS, often puTified. 
This was facilitated by the development of procedures for the in vitro 
transcription of tRNAs using T7 RNA polymerase (37, 108). Both 
methods have been extensively employed and together they have given us 
the rather comprehensive picture of aaRS specificity that has emerged in 
the past ten years. In general, the two methods agree but not always and 
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this is because they measure different though overlapping features of 
protein synthesis. 
The in vitro method measures the kinetics of the aminoacylation 
reaction but under conditions of salt, substrate, and enzyme 
concentration which may be quite different from that found in the cell 
(22). Furthermore, the rate-limiting step in vitro may not be relevant in 
vivo where the tRNA and aaRS concentrations may be very high. The 
in vivo method measures the outcome of the complex and important 
competition between all twenty aaRS for the same tRNA ( 4, 24, 44, 141-
143 ). However, the method cannot tell whether poor suppression is due 
to a failure to interact productively with the cognate aaRS or instead 
reflects a block in one of the many other steps leading to the eventual 
suppression step. These include transcription, processing and stability of 
the tRNA, interaction with elongation factor EF-Tu and the competition 
with the release factor in protein synthesis. A further complication of 
the in vivo method is that the anticodon of the tRNA must be CUA, 
recognizing the amber codon UAG. Since for most tRNAs, the 
anticodon is a crucial recognition element, this method in some cases 
would examine the identity of a tRNA which is impaired to begin with. 
To distinguish between the information obtained by the in vivo and 
in vitro approaches, workers in this field have adopted the term "identity 
elements" to distinguish those bases or structural featui-es of a tRNA 
which establish its specificity in vivo . These identity elements, can be 
either "positive" or "negative". Positive elements promote recognition 
by the cognate synthetase whereas negative elements are bases or 
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structural features which prevent the recognition of a tRNA by a non-
cognate aaRS. The "identity set" is the collection of identity elements in 
a set of tRNAs which allow those tRNAs to be recognized c01Tectly by 
the cognate aaRS. The term "recognition elements" refers to those bases 
or structural features which mediate specific recognition of a tRNA by 
its cognate aaRS in the in vitro aminoacylation reaction and the 
"recognition set" the collection recognition elements which confer in 
vitro specificity to a tRNA. Note that "negative identity elements" can in 
general only be identified through the in vivo approach. 
In cases where the two methods can be optimally employed, 
valuable complementary information can be obtained by determining 
both the "identity set" and the "recognition set" for a particular tRNA. 
This is the approach that we have taken in the study of serine identity, 
where extensive in vivo and in vitro studies have led us to an 
understanding of both the identity elements and recognition elements for 
this set of tRNAs. In this paper we employ both methods in a study of 
E. coli tRNALeu aaRS recognition. tRNA Ser and tRNALeu are two of 
only three sets of tRNAs in E. coli for which the anticodon is not a 
recognition element (the other being tRNAAla; (57)). Thus, they are 
uniquely suited for the valuable dual study that we have taken. Alleles of 
both tRNALeu and tRNASer were originally found as amber 
suppressors. For both tRNASer and tRNALeu there are six codons and 
therefore, in each case, sets of tRNAs with different anticodons are 
required. Both tRNAs are designated type II because they both possess a 
long base-paired extra stem loop, a feature of only the serine, leucine, 
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and tyrosine tRNAs in E. coli. As such, these tRNAs are ideally suited 
for identity swap experiments. In addition, to these reasons we were 
particularly interested to study tRNALeu identity because the 
information we have already obtained for tRNASer (36, 55, 65, 90) 
could be complemented with information of the tRNALeu identity set to 
provide an understanding of how these similar type II tRNAs are 
distinguished by their respective synthetases in the milieu of the cell. 
Considerable information on the recognition set of tRNALeu has 
already been published by Asahara et al. (130). These workers studied 
the in vitro aminoacylation of a number of tRNALeu variants and also 
carried out two in vitro experiments in which tRNASer and tRNATyr 
sequences were changed to yield variants with quite significant tRNALeu 
specificity. From their results, the following conclusions emerged: 1) 
The anticodon is likely not to be a recognition element since changing 
the anticodon of tRNALeucAG to tRNALeuuGA (a serine anticodon) 
did not significantly affect recognition by LeuRS. We have extended this 
result by making a more drastic set of anticodon changes and concur that 
the tRNALeu anticodon is not a recognition element. 2) The 
discriminator base; A 73 which is conserved in all E. coli tRNA Leu 
sequences, is recognized by LeuRS. 3) The tertiary A15-U48 Levitt 
base pair may be an important recognition element since it is among the 
changes necessary to redirect the amino acid specificity of tRNA Ser to 
tRNALeu. 4) All E. coli tRNALeu sequences have a characteristic 
dihydrouridine (D) loop which uniquely positions the conserved G 18 and 
G 19 bases relative to the D-stem. This positioning is also conserved in 
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tRNASer sequences but is different. The number of nucleotides 
preceding GI8 GI9 is one more in tRNALeu than in tRNASer and the 
number of nucleotides following GI8 GI9 is one less. In the Ser-Leu 
redirection experiment, it was crucial to insert UIS. I into the tRNASer 
D-loop and delete A21. 5) The extra-stem loop in the tRNALeu set is 
characterized by having one unpaired nucleotide between the base paired 
extra stem and the T-stem. In tRNASer there are no unpaired 
nucleotides between these two stems. While this extra-stem loop 
structure per se did not appear to be a recognition element, in the Ser-
Leu change it was necessary to engineer an unpaired nucleotide between 
the two stems. 
Despite this knowledge of the recognition elements of tRNALeu, it 
was not known which, if any of these elements were important in vivo, 
nor whether the changes affected only leucine identity. Changes to a 
tRNA could result in unanticipated acquisition of a different amino acid 
identity than the one intended or could fail (in recognition switch 
experiments) to remove the identity elements of the starting tRNA. 
However, with regards the likely non-participation of the extra stem-
loop in tRNALeu identity, there was agreement between in vitro and in 
vivo experiments. We had previously shown (90) that the type II extra 
loop in a tRNALeu amber suppressor tRNA can be replaced by a 
consensus type I loop, with no loss of leucine specificity. For both 
serine and tyrosine amber suppressors, this alteration results in a switch 
in specificity to glutamine. From these results it appeared that the extra 
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stem loop was not a leucine identity element in agreement with the in 
vitro results of Asahara et al. (130). 
That LeuRS does not recognize the extra stem loop was also 
indicated by alkylation protection experiments carried out by Dietrich et 
al. (131). In their experiments the interactions of tRNALeu with the 
heterologous bean cytoplasmic LeuRS were studied by determining 
which phosphates are protected from alkylation by ethylnitrosourea. 
The results indicate that LeuRS interacts with tRNALeu along the inside 
of the L-shaped tertiary structure on the opposite side from the extra 
stem loop. 
Subsequently, the determination of the structures of a number of 
tRNA-aaRS complexes rationalize this result. Synthetases have been 
divided into two general groups on the basis of exclusive sets of amino 
acid sequence motifs (15 , 89). Structural studies of tRNA-aaRS 
complexes have revealed that tRNAs interact differently with aaRS 
belonging to each group (9, 11, 13). Class I synthetases approach the L-
shaped tRNA structure from the minor groove face of the acceptor stem. 
In contrast, most class II synthetases are expected to approach the tRNA 
from its variable loop side which allows for interactions with the major 
groove of the acceptor stem. LeuRS belongs to class I and is expected to 
interact with the D-loop side of the tRNA. SerRS belongs to class II and 
recognizes the base-paired variable stem loop as well as functional 
groups in the major groove of the acceptor stem helix (13, 28, 55, 65, 
91). 
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In this study we have carried out an in vivo identity swap 
experiment to attempt the conversion of a tRNASer amber suppressor to 
leucine identity. In parallel, to understand further the role of the extra 
stem loop in tRNALeu, we have attempted to convert tRNASer~, an 
amber suppressor in which the type II extra stem loop had been 
substituted for a consensus type I loop, from its initial glutamine identity 
to leucine. In vitro aminoacylation assays for each of the tRNAs were 
performed using the competing synthetases, LeuRS, SerRS and GlnRS. 
While our results with the full length tRNA Ser to tRNALeu swap 
support and extend the results of Asahara et al. (130), the results with 
the extra-stem loop deletion body (tRNASer~) reveal additional leucine 
identity elements that may play an important role in the complex in vivo 
competition of the 20 aaRS for tRNALeu. 
MATERIALS AND METHODS 
Materials 
L-[3-3H] leucine (S .A. 54 Ci/mmole), L-[3-3H] serine (S.A. 30 
Ci/mmole), and L-[3-3HJ glutamine (S.A. 46 Ci/mmole) were purchased 
from Amersham. DNA oligonucelotides were synthesized by the 
California Institute of Technology Biopolymer Synthesis Center on an 
Applied Biosystems DNA/RNA Synthesizer 394 (Perkin/Elmer). 
Native tRNA Ser and tRNALeu were purchased from Subriden RNA. 
The restriction endonuclease BstN I and the plasmid pUC19 were 
purchased from New England Biolabs. T7 RNA polymerase was 
purified as previously described (144). Sequenase and sequencing 
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reagents were from U.S. Biochemical. Polyethyleneimine was from 
Miles Laboratories. Leupeptin and aprotinin were from Boehringer 
Mannhein Biochemicals. E.coli inorganic pyrophosphatase, bovine 
serum albumin, phenylmethylsulfonyl fluoride, benzamidine, pepstatin 
A, and methotrexate agarose were from Sigma. DEAE sephacel was 
from Pharmacia. 
Strains and Plasmids 
E. coli XAC-1 is F'lacl373ZuJ J 8amproB+/iJ.(lacproB)xJ J JnalA, 
r~f, ara, argEam. Plasmid pGFIB-I and pDAYQ are described in (34, 
36, 93). 
Construction of tRNA genes 
The genes for the STL variants and tRNALeu~CUA were 
constructed by the ligation of six overlapping DNA oligonucleotides and 
were cloned into the EcoR I and Pst I sites of pGFIB-I. The genes for 
tRNALeucuA, tRNASercuA and tRNASer~CUA had been constiucted 
previously by Normanly et al. (36, 90) and cloned into the EcoR I and 
Pst I sites of pGFIB-I. We used PCR to add a T7 RNA polymerase 
promoter and a BstN I restriction site to each of these genes and 
subsequently cloned them into the EcoR I and BamH I sites of pGFIB-I. 
Because these genes, as well as the STL variants, are active amber 
suppressors, we infer that neither the T7 polymerase promoter nor the 
BstN I site influence the correct processing of the tRNA in vivo. The 
genes for tRNALeuuuu and tRNALeuuAA, which were consu·ucted 
for use in only the in vitro experiments, were cloned into the EcoRI and 
Pst I sites of pUC19. The sequence of each tRNA gene was determined 
using the chain-termination method (Sequenase, USB). 
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Efficiency Assay 
To determine the suppression efficiency of each amber suppressor 
variant, plasmids containing the suppressor tRNA were transfo1med into 
the E. coli lacIZam fusion strain, XAC-1. The level of B-galactosidase 
in this strain was compared to that of the isogenic wild-type strain XAC 
as described in (35). 
Specificity Assay 
The amino acid inserted by each tRNA variant was determined by 
constructing E. coli strains in which the tRNA variant and a reporter 
gene were co-expressed. In brief, a copy of the dihydrofolate reductase 
(DHFR) gene having an amber mutation at position 10 was expressed 
under the control of the tac promoter from the plasmid pDA YQ (36) 
and the tRNA variant was expressed from the compatible plasmid 
pGFIB-I. DHFR was expressed and purified as described below using a 
method described previously (36) with some modifications. Cells were 
grown in LB containing ampicillin (100 ug/ml) and chloramphenicol (30 
ug/ml) to an optical density (A595) of 0.6. At this point the DHFR was 
induced by adding IPTG to a final concentration of 1 mM, and the cells 
were grown for 4 hours longer. The cells were centrifuged and the 
pellet was resuspended in buffer A (50 rnM potassium phosphate pH 6.0, 
200 rnM KCl, 1rnMDTT,1rnMEDTA,100 µM PMSF). The 
resuspended cells were then sonicated three times ( 1 minute burst; 1 
minute sitting on ice). The crude lysate was clarified by 
ultracentrifugation at 40K for 2 hours. The nucleic acids were removed 
from the clear lysate by precipitation with 1 % polyethyleneimine. The 
DHFR remained in the supernatant and it was loaded to a methotrexate 
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sepharose column, reloading the flow-through four times using a 
peristaltic pump . The column was then washed with buffer B (200 mM 
potassium borate pH 9.0, 1 M KCl, 1 mM DTT, 1 mM EDTA) until no 
more protein was detectable in the eluate. The DHFR was eluted with 
buffer C (200 mM potassium phosphate pH 8.0, 1 M KCl, 1 mM EDTA, 
2 mM folic acid). The fractions containing DHFR were combined and 
dialyzed in buffer D ( 50 mM potassium phosphate pH 8.0, 1 mM DTT). 
The dialyzed sample was loaded on a DEAE-sephacel column, pre-
equilibrated in buffer D. The column was developed with a gradient of 
0-400 mM KCl in buffer D. The DHFR eluted at 250 mM KCI. The 
protein appeared homogeneous on a silver stained protein gel. The 
protein was dialyzed against water and was sequenced by Edman 
degradation at either the University of Southern California 
Microchemical Core Laboratory or the California Institute of 
Technology Protein/Peptide Micro Analytical Laboratory. 
Purification of the Synthetases 
E.coli LeuRS was purified from the E.coli MQ strain harboring 
the plasmid pLeuS 2 (101) leading to overproduction of LeuRS. Four 
liters of cells were grown at 370c to an optical density (A590) of 0.8 in 
LB medium supplemented with 100 µg/ml of ampicillin. After inducing 
with 1 mM IPTG, the cells were grown to an absorbance of 1.7. Thirty-
five grams of cells were harvested and resuspended in 60 ml of buffer A 
(50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 mM EDTA, 2 mM B-
mercaptoethanol, and 25 mM KCl), sonicated and centrifuged at 
100,000xg for 1 h at 40c. The protease inhibitors PMSF, leupeptin, 
pepstain A, benzamidine, and aprotinin were included throughout the 
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purification (104). Nucleic acid was removed from the lysate by 
precipitation with 1 % polyethyleneimine. LeuRS remained in the 
supernatant and was loaded to a 35 ml DEAE-sephacel column pre 
equlibrated with 10% glycerol Buffer A, and eluted with a gradient of 
50-300 mM KCl in 10% glycerol Buffer A. LeuRS in the active fraction 
pool was precipitated with 75 % (NH4)2S04. The pellet was redissolved 
in 5 ml Buffer B (50 mM Tris-HCl pH 7.5, 1 mM DTT, and 10 % 
glycerol) and dialyzed into 50 % glycerol Buffer B and stored at -200c. 
The LeuRS appeared homogeneous on a Comassie Blue-stained protein 
gel. Silver staining of 1 µg of protein revealed few minor bands. The 
specific activity of the purified LeuRS was 2.3 x 105 units/mg protein. 
One unit is defined as the amount of LeuRS required to aminoacylate 1.0 
nmole of tRNALeu per minute at 370c at 5 µM tRNALeu under the 
reaction conditions described in the aminoacylation reaction section. 
The protein concentration was established using the Bradford assay 
(BioRad) with bovine serum albumin as the standard, and was measured 
to be 40.6 mg/ml (360 µM). E.coli SerRS was purified as previously 
described (55) and GlnRS was purified following the protocol described 
by Soll and co-workers (97). 
in Vitro Transcription of tRNAs 
Plasmid DNAs were purified by equilibrium CsCl gradient 
centrifugation and were linearized by digestion with BstN I to obtain a 
transcription template allowing the synthesis of tRNAs with the proper 
3'-terminal CCA (37). The transcription reactions contained : 40 mM 
Tris-HCl (pH 8.3 at 250c), 20 mM MgCl2, 5 mM DTT, 1 mM 
54 
spermidine, 4 mM each NTP (pH 8.0), 10 mM GMP, 0.1 mg/ml BSA, 
0.5 units/ml inorganic pyrophosphatase, 26,000 units/ml T7 RNA 
polymerase and 0.1 mg/ml DNA template. The reaction mixtures were 
incubated for 4 hours at 400C, stopped by adding EDT A to a final 
concentration of 25 mM, phenol/chloroform extracted, ethanol 
precipitated, resuspended, and gel purified to single nucleotide resolution 
by electrophoresis under denaturing conditions (55). The native tRNAs 
were also gel purified. All tRNAs were eluted twice with 500 mM 
KOAc pH 5.4 at 4oc. The tRNAs were ethanol precipitated a total of 
four times, finally resuspended in 10 mM HEPES-KOH (pH 7.4) and 
stored at -200c. RNA concentrations were quantitated by measuring the 
absorbance at 260 nm of a nuclease-digested sample (55). Extinction 
coefficients were calculated from the sequences of the tRNAs. 
Aminoacylation Reactions 
The LeuRS concentrations used to measure the kinetic parameters 
of various substrates ranged from 6.2 nM to 135 nM depending on the 
activity of the substrate. In a series of optimization experiments we 
determined that optimum aminoacylation by LeuRS could be obtained in 
reactions containing 30mM Hepes-KOH buffer, pH 7.4 and 50mM KCI. 
In particular, this buffer and salt combination gave aminoacylation rates 
that were two-fold greater than those obtained using 30 mM Tris-HCl 
(pH 7 .5 at 25°C) . Moreover, whereas the aminoacylation rates using 
HEPES were linear during a 15 minute reaction period, they began to 
decline in Tris-HCl, presumably due to the deacylation activity of this 
nucleophilic buffer (22). For consistency in comparing the activity of a 
particular substrate with different aaRSs we used the HEPES/KCl 
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combination for all three aaRSs employed in this study. All reaction 
mixtures were incubated at 37oc and contained 30 rnM HEPES-KOH 
(pH 7.4), 5 mM MgC12, 50 mM KCl, 2 mM DTT, 2 mM ATP, 20 µM 
amino acid (S.A. 10 ci/mmole). SerRS reactions were performed in the 
presence of inorganic pyrophosphatase (55). 
All tRNAs were annealed by heating for three minutes at 800C in 
10 rnM HEPES-KOH (pH7.4), 5 mM MgCl2, and 0.05 rnM EDTA 
(145) at a concentration 2.5 times greater than their final concentration 
in the aminoacylation reaction and allowed to slow cool to 25oc before 
use. For the kinetic experiments, the tRNA concentrations ranged from 
0.2 to 1.6 rnM and were always at least 10-fold greater than the enzyme 
concentration. A final protein concentration of 0.2 mg/ml in each 
reaction was obtained by adding BSA. At appropriate time points, 
aliquots were spotted on dried Whatman 3MM paper pretreated with 
10% TCA and 100 µM amino acid. The spotted papers were washed two 
times with 10% TCA, three times with 5% TCA, and one time with 
ethanol for a period of time that reduced the residual background of 
3H-amino acid in a control reaction, not containing tRNA and 
independent of the aaRS concentration, to below 0.008% of the total 
radioactivity spotted. The counting efficiency of the 3H-leucine on the 
Whatman filter paper in fluor (consisting of 3.83 grams of 2,5-




Changing the Identity of a tRNASer to Leucine. 
The sequences of the five leucine tRNAs from E. coli (anticodons 
CAG, GAG , UAG, CAA, UAA), and a tRNALeu from bacteriophage 
T4 (anticodon UAA) were compared in order to detect specific residues 
that are likely to contribute to recognition by this synthetase. The T4 
leucine tRNA is known to be aminoacylated by E.coli LeuRS (106). 
Figure 1 shows that there are 33 nucleotides which are conserved among 
these tRNAs. Of these, 14 occur in nearly all tRNAs and thus are not 
anticipated to differentially dictate recognition. This left 18 nucleotides 
that might either directly or indirectly dictate specific aminoacy lation by 
LeuRS. Since our interest was in determining the nucleotide changes 
that were necessary to redirect the in vivo amino acid identity of a 
tRNASer to leucine, we excluded from consideration the 5 nucleotides 
that are found in both E. coli leucine and serine tRNAs as well as A35 of 
the anticodon. This left 12 nucleotides that differed between these two 
types of tRNAs and that might therefore account for their different 
amino acid identities under conditions where both synthetases are 
competing for the same substrate. Transplanting some or all of these 
nucleotides into tRNASer was therefore expected to be necessary for the 
acquisition of leucine identity. We additionally considered whether it 
was necessary to change other nucleotides in tRNASer in order to 
discourage aminoacylation by SerRS. 
At the outset, it was necessary to determine the consequence of 
using amber suppressors for both the in vivo and in vitro assays. The 
anticodon is a crucial recognition element for most tRNAs (42, 51). 
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Thus the nucleotide changes that result when an amber (CUA) anticodon 
is transplanted into any tRNA can potentially redirect tRNA amino acid 
identity (33, 105) or, when the correct amino acid is inserted, the tRNA 
may nonetheless be impaired in aminoacylation efficiency with respect to 
the cognate synthetase (34, 58, 59). The existence of amber suppressing 
alleles of both tRNALeu and tRNASer which retain their original amino 
acid identity showed that any change in aminoacylation efficiency by the 
cognate synthetase was not sufficient to redirect amino acid identity in 
the cell. Subsequent in vitro aminoacylation kinetic determinations using 
SerRS (55), as well as the tRNASer_serRS cocrystal structure (13) 
definitively showed that SerRS does not recognize nucleotides in this 
region of the tRNA. A similar situation was anticipated for tRNALeu 
based on the existence of leucine inserting amber suppressors as well as 
from in vitro aminoacylation assays which showed that changing the 
tRNALeu anticodon from CAG to UGA had no appreciable effect on 
aminoacylation by LeuRS (130). Nevertheless, the effect of an amber 
anticodon (CUA) on aminoacylation by LeuRS had not been directly 
determined. 
Table 1 shows that changing the tRNALeu anticodon from UAA to 
CUA decreased kcat/Km of aminoacylation by LeuRS by only about five 
fold. Due to the degeneracy of the genetic code, N36 of the leucine 
anticodon is n01mally a purine (either A36 or G36). Thus the possibility 
existed that neither the serine (UGA) nor the amber CUA anticodon 
affected aminoacylation by LeuRS because they present a required A36. 
This possibility was tested using a tRNALeu variant having the anticodon 
UUU (lysine). As indicated in Table 1, this anticodon transplant had 
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only a trivial effect on aminoacylation by LeuRS. Thus in vivo and in 
vitro assays consistently indicate that E. coli LeuRS does not specifically 
recognize the anticodon of its cognate tRNAs. However, the anticodon is 
an important determinant of aminoacylation specificity for GlnRS (53, 
146). So while the presence of the amber anticodon should not affect the 
competitive balance between LeuRS and SerRS, its presence in the tRNA 
variants described below is likely to alter the competitive balance by 
promoting aminoacylation by GlnRS. 
Figure 2 shows the changes we selected for an initial Ser-Leu 
transformation (STL2). Many of the changes we have inserted are 
expected to affect the tertiary structure of the tRNA. These changes 
were made based on the tertiary interactions that are revealed in the 
crystal structures of tRNAPhe and tRNAAsp and the SerRS-tRNASer 
cocrystal structure (7, 8, 10, 13). The Gl5-C48 ("Levitt" tertiary base 
pair (147) of tRNASer was changed to Al5-U48 for several reasons. An 
Al5-U48 base pair is conserved among leucine tRNAs (Figure 1) and is 
commonly found within this isoaccepting group. Moreover, it is not 
found in other type II tRNAs. Finally, this base pair is expected to 
dictate tRNA tertiary structure and might thereby affect the positioning 
of other nucleotides that are directly recognized by LeuRS. The position 
of G 18andG19 within the D-loop differs among tRNAs could also 
contribute to subtle variations in the tRNA tertiary structure. In 
particular, G 18 and G 19 are typically preceded by three nucleotides and 
followed by four nucleotides in serine tRNAs but just the opposite 
configuration is found in leucine tRNAs. The tRNALeu configuration 
was obtained by introducing an insertion and a deletion into the tRNASer 
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D-loop. As a consequence of these changes, G20b of tRNA Ser 
potentially took on the role of the unusual G21 of leucine tRNAs. The 
Cl0-G25 base pair of the tRNA Ser D-stem was changed to G 10-C25 and 
A59 was changed to G so that the nucleotides at these positions 
conformed to those conserved among leucine tRNAs. An unpaired 
nucleotide was inserted at position 47n of tRNA Ser between the extra 
stem-loop and the T-stem since this configuration is found in leucine but 
not serine tRNAs. In addition to introducing a portion of the conserved 
tRNALeu sequence into tRNASer, the insertion at position 47n, in 
conjunction with the deletion of A21, probably alters both the A21-[U8-
Al4] tertiary base pair as well as the base stacking interactions between 
G20b and the 45-47m base pair that normally occur in serine tRNAs 
(13). Consequently, it is likely that both the core structure of tRNASer 
as well as the orientation of the extra stem-loop were changed in a 
manner that discouraged aminoacylation by SerRS. STL2 was designed 
prior to the publication of the tRNASeLSerRS cocrystal structure (13) 
and thus before the determinants of the extra stem-loop orientation in 
tRNASer were known. In the type I yeast tRNAPhe, the G26-A44 
"propeller" base pair stacks on G45 of the variable loop (7, 8). Thus the 
possibility existed that a similar type of base stacking interaction might 
affect the orientation of the extra stem-loop structure in tRNASer. The 
A26G substitution was introduced in an attempt to alter this putative 
interaction. Finally, STL2 contains changes at position 73 and in the 
base pairs at positions 2-71 and 3-70 of the acceptor stem in order to 
recapitulate the sequence found in leucine tRNAs. Although the base 
pair at position 3-70 is not absolutely conserved among leucine tRNAs 
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(Figure 1), the G-C and C-G base pair alternatives at this position do 
conserve an exocyclic amino group in the minor groove. The change to 
C-G was suggested by a statistical study of tRNALeu sequences which 
showed that the most commonly used leucine tRNA in E. coli contains a 
C3-G70 base pair (3). 
We have carried out both in vivo and in vitro assessments of the 
activity of STL2 and a number of variants of this tRNA. Prior to the in 
vitro kinetic experiments we tested each of the STL substrates in 
preliminary aminoacylation expeliments with LeuRS, SerRS and GlnRS 
to confi1m that each tRNA could be completely charged, affi1ming that 
the transcript was not grossly mis-folded. Thus these experiments 
provide a positive control for substrates exhibiting poor kinetic constants 
for a particular aaRS (Figure 3). 
The mutant STL2 is a good suppressor, 75% efficient as measured 
using the B-galactosidase assay, and it exclusively inserts leucine. The in 
vitro kinetic experiments revealed a kcat/Km of aminoacylation by 
LeuRS that was only about 6 fold lower than that of the native tRNALeu. 
On the other hand, STL2 is an extremely poor substrate for SerRS 
(Table 1) indicating that the nucleotide changes have disrupted 
interactions with this synthetase. Sixteen changes are therefore sufficient 
to convert a tRNASer into a tRNALeu. 
What remained to be determined was whether structural features, 
the acceptor stem sequence or both types of elements were necessary for 
the Ser-Leu transformation. The variant STL8 has the same structural 
alterations as STL2 but lacks the changes in the acceptor stem and at 
position 73 . It is a good suppressor, 50% efficient as measured using the 
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B-galactosidase assay. Although it inserts a substantial amount of 
leucine, it is additionally a substrate for GlnRS, HisRS and SerRS under 
in vivo conditions (Figure 2). The in vitro aminoacylation assays are 
consistent with this observation. STL8 had a kcat/Km of aminoacylation 
by LeuRS that was 120 fold lower than that of wild type tRNALeu. 
Although the in vitro aminoacylation assays showed that STL8 was an 
extremely poor substrate for SerRS, interestingly a small proportion of 
STL8 is aminoacylated with serine under in vivo conditions. Together, 
the results for STL8 indicate that the structural changes, alone, are not 
sufficient to redirect the amino acid identity of tRNASer. 
Two types of changes were introduced into the tRNA Ser acceptor 
stem in order to recapitulate the tRNALeu acceptor stem sequence: 
changes in the acceptor stem and at position 73. STL 7 lacks the acceptor 
stem changes but retains A 73 . Both STL2 and STL 7 are very good 
suppressors and exclusively insert leucine under in vivo conditions. The 
in vitro aminoacylation assays revealed that LeuRS recognizes STL2 and 
STL 7 with a similar efficiency; the kcat/Km of STL2 and STL 7 was only 
6.3 and 8.4 fold lower, respectively, than the wild-type substrate. Thus 
it was not necessary to change the base pairs of the helical acceptor stem 
in order to affect a Ser-Leu identity swap within the context of the 
structural changes that were introduced into the full length tRNASer. 
The second type of change in the acceptor stem involves the 
single-stranded "discriminator" nucleotide at position 73. E. coli serine 
tRNAs always have a guanosine at this position whereas in leucine tRNAs 
it is exclusively an adenine. The sequences of STL 7 and STL8 only 
differ with respect to the nucleotide at position 73 . STL 7 and STL8 
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were good suppressors (50 and 80 percent, respectively). However, 
whereas STL7 exclusively inserts leucine, STL8 had a mixed amino acid 
identity (Figure 2). Interestingly, kcat/Km of aminoacylation by LeuRS 
differs between these variants by only a factor of about 14 fold. Thus 
A 73 contributes to aminoacylation by LeuRS and its presence appears to 
affect the outcome of the competition among synthetases. 
A second set of tRNA Ser variants was constructed to examine 
whether the nucleotides necessary to promote aminoacylation by LeuRS, 
both in vivo and in vitro, differ as a function of the structural 
framework in which they are embedded. Such an effect might be 
anticipated if the structural framework affects the orientation of 
recognition nucleotides in three-dimensional space and thus affects the 
accessibility of critical nucleotide functional groups (39). In addition, 
the structural framework could influence the stabilization of a transition 
state complex that is necessary for catalysis. Consequently, a change in 
the tRNA structural framework could not only affect recognition by the 
cognate synthetase but might also promote recognition by a non-cognate 
synthetase affecting the set of synthetases which are competing for a 
given substrate. 
We had previously engineered a variant, tRNALeu~, in which the 
type II extra stem-loop of a tRNALeu amber suppressor was replaced by 
a consensus type I loop with no loss of leucine specificity (90). This 
result suggested that the tRNALeu extra stem-loop structure is a 
dispensable element in vivo and unlikely to be in direct contact with 
LeuRS, a conclusion that was consistent with the results of footprinting 
studies of leucine tRNAs and LeuRS (131). Although LeuRS does not 
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directly contact the extra stem-loop, changes in this region of the tRNA 
were not without effect; the kcat/Km of aminoacylation by LeuRS is 
reduced by about 40 fold when the extra stem-loop of tRNALeucuA is 
replaced with the type I consensus loop to give tRNALeu~CUA (Figure 
4 and Table 1). 
In contrast, the tRNASecserRS cocrystal structure (13) shows 
that SerRS directly contacts the tRNASer extra stem-loop. Moreover, 
both in vivo (90) and in vitro (55, 137, 138) assays show that this 
structural feature makes a large contribution to serine specificity. 
Interestingly, when the type II extra loop in a tRNASer amber 
suppressor is replaced with a consensus type I loop to create tRNA Ser~, 
the variant exclusively inserts glutamine, rather than serine, in the in 
vivo DHFR assay (90). Thus tRNASer~ provides an interesting scaffold 
for examining the requirements for leucine identity. Importantly, even 
though tRNASer and tRNASer~ only differ with respect to nucleotides 
in the region of the extra loop, they are substrates for two different 
synthetases. 
The variant STL3 is analogous to STL2. It has the full 
complement of nucleotide changes seen in STL2 but instead of the type II 
extra stem-loop, STL3 has a consensus type I variable loop. Whereas the 
in vivo assay showed that STL2 inserted only leucine, STL3 
predominantly inserts leucine (93%) and a small amount of glutamine 
(7%). Thus the same set of nucleotide changes in the STL2 and STL3 
structural frameworks had a slightly different outcome. The results of 
the in vitro aminoacylation assays are consistent with these observations: 
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the kcat/Km of aminoacylation by LeuRS of STL2 is about 4 fold greater 
than that of STL3, primarily due to a difference in Km. 
The variant STLS has the same structural alterations as STL3, but 
lacks the changes in the helical acceptor stem and at position 73. 
Although both tRNAs are efficient suppressors, they differ in amino acid 
identity. STL3, the variant having the tRNALeu acceptor stem sequence, 
inserts leucine in the DHFR assay, whereas STLS which lacks these 
changes exclusively inserts glutamine. The in vitro aminoacylation 
assays showed that STL5 is an extremely poor substrate for LeuRS 
(Table 1). The possibility that the tRNA is improperly folded is ruled 
out by the fact that STL5 can be aminoacylated to nearly 100% by 
GlnRS (Figure 3). It is striking that removing the tRNALeu acceptor 
stem discriminator base sequences from the full length tRNA scaffold 
(STL2 vs STL8) decreased kcat/Km of aminoacylation by LeuRS by 120 
fold compared to a wild type tRNALeu while their lack in the tRNASer~ 
scaffold (STL3 vs STLS) rendered STLS unchargeable by LeuRS (Table 
1 ). 
Comparison of the data for STL3 and STL6 indicates that the 
sequence of the helical acceptor stem plays a role in dictating tRNA 
amino acid identity within the structural scaffold lacking the extra stem-
loop. This is reflected by the results of the assay which reveal that STL3 
inserts 93% leucine and 7% glutamine while STL6 only inserts 66% 
leucine and 34% glutamine. The in vitro aminoacylation assays show a 
similar trend. The kcat/Km of aminoacylation by LeuRS of STL3 is 23 
fold lower than that of a wild type tRNALeu whereas the kcat/Km of 
STL6 is 3000 fold lower. However the results for STL3 and STL6 are 
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striking in that a large difference in the in vitro aminoacylation kinetics 
of these two tRNAs with respect to LeuRS results in a rather modest 
difference in their amino acid specificities within the cellular 
environment. 
The effect of A 73 on recognition by LeuRS is revealed by 
comparing the data for STL5 and STL6 whose sequences only differ 
with respect to the nucleotide at position 73. STL5, having a G73, 
inserts 100% glutamine whereas STL6, having an A 73 inserts only 34% 
glutamine and 66% leucine. Thus the G73A substitution, which 
introduces the conserved A 73 of E.coli leucine tRNAs, markedly 
increases the amount of leucine that is inserted into the reporter protein. 
This identity change seems to stem, in part, from an improvement in the 
aminoacy lation efficiency by LeuRS since the kcat/Km of STL6 (A 73) 
and STL5 (G73) differ by a factor of at least 4. Nevertheless, STL6 is a 
poor substrate for LeuRS having a kcat/Km of aminoacylation that is 
3000 fold lower than that of a wild-type tRNALeu (Table 1 and Figure 
2). STL6 can be aminoacylated to 80% when high enzyme 
concentrations and long time periods are used (Figure 3 ), iuling out the 
possibility that it is grossly misfolded. Thus although an A 73 in the 
tRNA~ framework contributes to recognition by LeuRS, it is not 
sufficient to entirely confer leucine identity in vivo nor to confer 
efficient aminoacylation by LeuRS. 
The difference in the amino acid identities of STL5 and STL6 
appears to stem from an influence of the nucleotide at position 73 on 
recognition by GlnRS as well as LeuRS. Whereas nearly 100% of the 
input STL5 was aminoacylated in ten minutes using an excess of GlnRS, 
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only about 10% of STL6 was aminoacylated in this time period using the 
same enzyme and substrate concentrations (Figure 3). Given the 
conditions used for these experiments, it is not possible to ascertain 
absolute differences in the aminoacylation efficiencies of these two 
substrates. Nevertheless, it is clear that there is a qualitative 
improvement in aminoacylation by GlnRS when the G73 (STL5) as 
opposed to the A 73 (STL6) is present. Moreover, it is well established 
that G73 in the wild-type tRNA Gln is a recognition element for GlnRS 
(11, 53). 
In the variant STL9 (Figure 5) we attempted to obtain the Ser-Leu 
transformation utilizing a minimum number of changes: the G73A 
change, nucleotide substitutions which presumably altered the orientation 
of the extra stem-loop, and the introduction of the Al5-U48 "Levitt" 
base pair. STL9 is only 10% efficient, as measui-ed by the b-
galactosidase assay but it inserts 100% leucine. Its kcat/Km of 
aminoacylation by LeuRS was only about 8 fold lower than that of a 
wild-type tRNALeu. Moreover, it was a very poor substrate for SerRS 
having a kcat/Km that was 2300 fold lower than that of a wild-type 
tRNA Ser. Thus only six changes are required to transform tRNA Ser 
into a tRNA that accepts only leucine in the cell and that has near wild 
type activity with respect to LeuRS. 
In an attempt to delineate the necessity of these changes, we 
designed two additional variants. In STL12 the "Levitt" base pair is 
reverted to the sequence that is normally found in serine tRNAs but all 
other changes are preserved. This variant is a rather poor suppressor 
(1 % efficient) and is not aminoacylated with leucine in the cell. Rather, 
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it has an amino acid identity that is 95% serine and 5% tyrosine. This 
indicates that the Al 5-U48 "Levitt" base pair characteristic of leucine 
tRNAs is critical to their amino acid identity. The Al5-U48 "Levitt" 
base pair is retained in STL13 as is the G73A change. However, in this 
variant the D-loop and extra stem-loop sequences are reverted to those 
of serine tRNAs. STL13 has an efficiency of 40% but it is not 
aminoacylated with leucine in the cell. Rather, it inserts 97% serine and 
3% tyrosine. This indicates that the Al5-U48 "Levitt" base pair and 
A 73 are not sufficient to ensure leucine identity. Thus the in vivo results 
show that the D-loop, extra stem-loop and the G73A substitutions 
(STL9) are all required for the complete transformation of a tRNASer 
into a tRNALeu under conditions where all 20 synthetases are competing 
for substrates. Asahara and coworkers (130) showed that kcat/Km of 
aminoacylation by LeuRS was decreased by about 280 fold when the 
Al5-U48 base pair was reverted to Gl5-C48 (as in STL12). In addition, 
kcat/Km of aminoacylation by LeuRS was below detectable limits for a 
variant having an A 73 and the Al 5-U48 base pair but in which the D-
loop and extra stem-loop were in the tRNASer configuration. Thus the 
in vitro and in vivo results for these minimal substrates are in 
agreement. 
DISCUSSION 
The nucleotides which determine tRNA amino acid specificity can 
be identified using either an in vitro or an in vivo approach. In vitro 
studies typically focus on the determinants of cognate interactions. The 
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results obtained using the in vivo approach reflect the outcome of the 
competition between the cognate aaRS and any unfortuitous interactions 
between the tRNA and non-cognate synthetases. In our earlier in vivo 
study of tRNA Ser identity we showed that eight changes were necessary 
to convert a tRNALeu amber suppressor to serine identity (36, 90). 
Subsequent in vitro studies elucidated the recognition elements of 
tRNA Ser (55, 65, 137, 138). In this paper we examine the determinants 
of amino acid specificity for E. coli tRNALeu by attempting the opposite 
transformation: redirecting the specificity of a tRNASer amber 
suppressor to leucine identity. Both tRNA Ser and tRNALeu are type II 
tRNAs containing a large extra stem loop. In addition to transforming 
tRNA Ser to tRNALeu, a "type II swap," we attempted a "type I swap," 
the transformation of amber suppressor tRNASer~ to leucine identity. 
tRNASer~ was constructed earlier to explore the role of the type II stem 
loop strncture in serine identity (55, 90) In this tRNA the base paired 
extra stem-loop common to type II tRNAs is replaced by a consensus 5 
base extra loop characteristic of type I tRNAs. This type !'amber 
suppressor inserts glutamine so this is a Gln-Leu swap. For each of the 
tRNA variants we determined both the in vivo identity and also 
determined the in vitro specificity for aminoacylation by LeuRS, SerRS 
and GlnRS. This combination of both in vivo and in vitro methods is 
useful because each gives a different perspective on the complex 
interactions that determine tRNA identity in the cell. 
For our in vivo approach, each tRNA variant must have the CUA 
amber anticodon. This can influence the experimental outcome in two 
ways. In cases where the cognate synthetase recognizes the anticodon, 
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nucleotide substitutions creating the amber (CUA) anticodon can weaken 
that interaction (34, 58, 59) and might thereby facilitate the acquisition 
of a new identity when additional changes are made. The amber 
anticodon can also directly promote interactions with a non-cognate 
synthetase changing the identity of the tRNA (33 , 105). Since neither 
SerRS (13, 55) nor LeuRS ((130) and Table 1) recognizes the anticodon 
of the cognate tRNA, the tRNASer to tRNALeu transformation is ideal 
for this approach. Nevertheless, because the amber anticodon provides 
recognition elements for GlnRS (23, 53, 146), introduction of the amber 
anticodon was not entirely without consequence. Indeed, competition 
between SerRS, LeuRS and GlnRS for the amber suppressor tRNA is 
revealed by the in vivo data (Figures 2 and 5). Importantly, tRNASerLi 
has glutamine identity (90). Thus the identity swap being attempted in 
this case is from glutamine to leucine. 
In the type II swap, six changes, five affecting the tertiary 
structure and one in the discriminator base, were necessary and 
sufficient to completely change the identity of the full length tRNASer 
amber suppressor to leucine. The tertiary changes involved the 
configuration of the D-loop, the 3'-end of the extra stem-loop, and the 
trans-tertiary Al5-U48 "Levitt" base pair. (STL9; Figure 5). 
a). The discriminator base. 
The variants STL 7 and STL8 have the same nucleotide changes 
embedded in a full length tRNASer scaffold and differ only in position 
73. The in vivo assays reveal that if the discriminator base is G, as in 
STL8, the variant inserts 66% leucine but it also inserts glutamine, 
histidine and serine. However, when the discriminator base is changed 
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to A, the variant inserts only leucine. The in vitro aminoacylation assays 
revealed that STL8 (G73) has a kcat/Km of aminoacylation by LeuRS 
that is about 14 fold lower than that of STL 7 (A 73). The same 
substitution in a tRNALeu reduces Vmax/Km by about 160-fold (130). 
In contrast, aminoacylation by SerRS and GlnRS was relatively 
unaffected by the nucleotide at position 73 (Figure 3 and Table 1). Thus 
a positive effect of A 73 on recognition by LeuRS appears to account for 
the different amino acid identities of STL 7 and STL8. 
It was not possible to estimate the individual kinetic parameters or 
STL8 for LeuRS using the tRNA concentrations employed in this study. 
Nevertheless, it appears that the relatively low specificity constant of 
STL8 is due, in part to an elevated Km. We estimate this value to be no 
less than 15µM since at this concentration the initial velocity was 
proportional to the substrate concentration. An effect of the 
discriminator base on Km is somewhat unexpected given the close 
proximity of this nucleotide to the synthetase active site at the time of 
amino acid transfer. However, an elevated Km has also been reported 
for a G73A substitution in a tRNALeu (130). Moreover, an elevated 
Km is consistent with the in vivo results. There was little, if any, 
difference in the aminoacylation specificity of STL8 and STL7 for 
GlnRS and SerRS; yet STL8 had a mixed amino acid identity whereas 
STL 7 did not. It is possible that as a consequence of the relatively high 
Km of STL8 for LeuRS, the concentration of free STL8 in the cell was 
elevated to an extent that allowed GlnRS and SerRS to effectively 
compete for this substrate. Indeed, tight binding among cognate pairs 
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can be an essential determinant of tRNA amino acid identity (4, 142) as 
can the tRNA and synthetase concentrations (24, 44, 141, 143). 
b). The Al5-U48 tertiary base-pair. 
The contribution of the Al5-U48 tertiary base pair to leucine 
idenity was revealed by comparing the amino acid identity of STL9 to 
that of STL12 (Figure 5). Both STL9 and STL12 have the tRNALeu 
A 73, D-loop configuration and the unpaired nucleotide at the 3'-end of 
the extra stem-loop. However, whereas STL9 has the tRNALeu Al5-
U48 base pair, STL12 has the Gl5-C48 base pair of tRNASer. STL9 
inserted only leucine, but STL12 inserted 95% serine and 5% tyrosine. 
Thus an Al5-U48 base pair is essential for leucine identity. The in vitro 
studies of Asahara et al. (130) confirm that this base pair is an important 
recognition element. As we shall see below it is likely to be the trans-
tertiary interactions that this base-pair participates in trans-tertiary 
interactions that are important for its role in leucine identity. 
c). The D-loop configuration and the orientation on the extra 
stem-loop . 
All E.coli leucine tRNAs have a characteristic D-loop in which 
there are three unpaired nucleotides before the conserved G 18 G 19 and 
two after. In contrast, all serine tRNAs have the opposite configuration, 
two before and three after. These features are believed to contribute 
unique characteristics to the tertiary structure of the tRNA through their 
effects on positioning Gl8 and Gl9 which form tertiary base-pairs with 
Y55 and C56 in the T-loop (7, 8, 10). In addition all leucine tRNAs 
have a single unpaired base between the type II base-paired extra stem 
and the T stem. In E. coli serine tRN As there are none. The 
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characteiistic conformation of the D-loop and the nucleotides at the base 
of the extra stem are linked features, at least in tRNA Ser, because there 
is a stacking interaction between the 45-47q base-pair and G20b that 
cannot take place in tRNALeu where neither the base-pair nor G20b 
exist (13). Moreover in this context, the G 15-C48 base-pair in tRNA Ser 
interacts with the dihydrouridine (D) at position 20a to form a base 
triple which influences the tRNA tertiary fold (13), an unlikely 
interaction in tRNALeu. These tertiary interactions are doubtless 
intenupted in the successful STL constructs although what replaces them 
or what their counterparts might be in tRNALeu will not be known until 
we have a tRNALeu structure. 
The contributions of the D-loop and extra stem-loop features to 
leucine identity were revealed by comparing the amino acid identity of 
STL9 to that of STL13. Both STL9 and STL13 have the leucine A73 
and Al5-U48 tertiary base pair. And while STL9 has the tRNALeu 
configuration in the D-loop and extra stem-loop, in STLl 3 the 
configuration is reverted to the one found in tRNASer. STL9 inserted 
only leucine, but STL13 inserted 97% serine and 3% tyrosine. Thus 
Al 5-U48 cannot confer identity in the absence of a characteristic D-
loop/extra stem loop configuration. It is striking that most of the 
important identity elements in tRNALeu involve linked determinants of 
its tertiary structure. 
It seems likely that the different D-loop and extra stem-loop 
configurations of STL9 and STLl 3 concomitantly affect recognition by 
both LeuRS and SerRS, but in opposing ways. STL9 is aminoacylated by 
LeuRS with an efficiency that is only about 8 fold lower than that of a 
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wild type tRNALeu whereas it is aminoacylated by SerRS with an 
efficiency that is more than 2000 fold lower than that of tRNASer 
(Table 1). Although aminoacylation kinetics were not determined for 
STLl 3, it seems likely that it has just the opposite properties of STL9. 
STL13 is expected to be a poor substrate for LeuRS based on the results 
of A sahara and coworkers (130) who reported that V max/Km of 
aminoacylation by LeuRS of a tRNA variant having a sequence similar to 
that of STL13 was more than 5000-fold lower than a substrate 
resembling STL9. In contrast, STL13 is expected to be a good substrate 
for SerRS because it retains the 45-479 base pair and the location of the 
tRNASer G20b which affects the orientation of the extra stem-loop 
structure contributing to tRNASer recognition (13). 
Based on the above observations, it appears that some of the 
determinants for recognition by SerRS and LeuRS reside in the same 
region. However, the mechanisms that account for the effect of these 
nucleotides on recognition by the cognate appear to differ. SerRS 
directly contacts the extra stem-loop structure (13). Thus nucleotide 
changes that alter the orientation of this structure are expected to affect 
aminoacylation by SerRS. In contrast, a direct contact between LeuRS 
and the extra stem-loop seems unlikely. We have shown that the 
tRNALeu extra stem-loop can be replaced with the consensus type I 
variable loop with no loss of leucine identity (90) and that this change 
decreases kcat/Km of aminoacylation by LeuRS by only about 40 fold 
(Table 1; cf. Leu CUA and Leu~CUA ). Moreover, the results of 
alkylation protection experiments using E. coli tRNALeu and the 
heterologous bean cytoplasmic LeuRS revealed no protection of this 
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structure (131 ). Instead, the experiments revealed protection on the 5'-
and 3 '-sides of the D-stem indicating that LeuRS binds the inside of the 
L-shaped tRNA st1ucture. This binding topology, perhaps generating a 
different angle between the two helical arms of the tRNA or subtly 
different confo1mations of the backbone along the inside of the "L", 
provides a possible means by which LeuRS can discriminate between the 
subtly different tRNA tertiary structures in tRNALeu and tRNASer. 
d) The Type I swap: tRNASerlLtRNALeu 
In a second set of variants, the tRNA structural framework was 
changed by replacing the extra stem-loop of tRNA Ser with the consensus 
variable loop of type I tRNAs to give tRNA Ser~. This changed the set 
of synthetases that were competing with LeuRS as well as the sttuctural 
framework within which the acceptor stem and discriminator base were 
presented to LeuRS. tRNASer~ has glutamine amino acid identity, in 
vivo, (90). When the tRNALeu D-loop configuration and A15-U48 base 
pair are embedded within this framework to give STL5, the amino acid 
identity is still glutamine. The in vitro aminoacylation assays revealed 
that STL5 is an exu·emely poor substrate for LeuRS but that it is 
aminoacylated to nearly 100% by glutamine synthetase (Figw·e 3 and 
Table 1), ruling out the possiblity that the variant is incorrectly folded. 
Comparison of the data for STL5 and STL6 reveals the influence of A 73 
in the tRNA Ser~ framework. Whereas STL5 had an in vivo amino acid 
identity that was completely glutamine, STL6 inserts 34% glutamine and 
66% leucine. The in vitro aminoacylation assays revealed that 
aminoacylation of STL5 by LeuRS was below detectable limits but is 
improved somewhat by the introduction of A 73 (Table 1 ). While A 73 
75 
was sufficient to completely confer STL 7 with a leucine identity in the 
type II swap, it improved but did not completely confer leucine identity 
in the type II experiment. Comparison of the data for STL6 and STL3 
reveals the influence of the tRNALeu acceptor stem sequence. 
Substitutions in this region of the tRNA account for an additional 
increase in leucine identity, and a substantial increase in aminoacylation 
efficiency by LeuRS, rendering STL3 a good though not perfect leucine 
suppressor since it still inserts 7% glutamine (Table 1 and Figure 2). In 
contrast, the acceptor stem changes were not necessary within the full 
length tRNA background (cf. STL 7 and STL2; Figure 2). 
Two factors appear to account for our ability to achieve a 
complete identity swap in the type II body while not accomplishing it 
completely in the type I body. GlnRS competes poorly with LeuRS and 
SerRS for the full length variants even though each of these has an 
amber (CUA) anticodon which provides recognition elements for GlnRS. 
Thus the Ser-Leu transformation primarily depended on substitutions 
which depressed aminoacylation by SerRS and increased aminoacylation 
by LeuRS. Since some of the determinants for recognition by SerRS and 
LeuRS reside in the same region of the tRNA, it was possible to 
introduce nucleotide substitutions which had opposing effects on these 
two synthetases. In contrast, GlnRS is able to compete effectively with 
LeuRS and SerRS for the tRNASer~ variants. This is evidenced by the 
fact that tRNASer~ has a glutamine identity. Thus the acquisition of a 
leucine identity in the tRNA~ background necessitated substitutions that 
increased aminoacylation by LeuRS and that decreased aminoacylation 
by GlnRS. The in vitro assays show that increased aminoacylation by 
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LeuRS was achieved by introducing all of the conserved tRNALeu 
nucleotides into the tRNASer~ background (STL3; Figure 2). However, 
these substitutions did not compeletely suppress aminoacylation by 
GlnRS since STL3 still accepts some glutamine. Whereas the consensus 
leucine acceptor stem is expected to decrease aminoacylation specificity 
of the tRNA for GlnRS since it lacks some of the tRNA Gin recognition 
elements (11, 52, 53), STL3 retains recognition elements for GlnRS in 
its anticodon. Thus a complete identity swap was hampered by the 
different locations of recognition elements for LeuRS and GlnRS. 
Two potentially important differences in the tertiary structures of 
the type II and type I variants may be a second, and related factor, 
influencing the success of the identity swap experiments. First, the 
tRNA~ variants have a single-stranded uridine rather than guanosine at 
the 3 '-end of the variable loop. The results of Asahara et al. (130) when 
compared to ours indicate that the nucleotide at this position does not 
play a significant role in dictating recognition by LeuRS (our constructs 
have a G in that position, theirs have a U) However, it remains unclear 
whether U47 in the tRNASer~ framework and G47n in the full length 
tRNA backgrounds are in functionally equivalent positions. This could 
be critical if N47n plays a role in dictating the tertiary structure of 
tRNALeu. Second, in replacing the extra stem-loop with the type I 
consensus sequence, we may have inadvertently affected base triples so 
that the full length and tRNA Ser~ variants have subtly different tertiary 
structures. 
In the type II tRNA framework, it was not necessary to introduce 
changes into the helical acceptor stem in order to affect a Ser-Leu 
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identity swap. In addition, nucleotide substitutions in the acceptor stem 
resulted in only a minimal improvement in aminoacylation by LeuRS 
(Figure 2 and Table 1). In contrast, in the type I framework, the 
acceptor stem substitutions were necessary for leucine identity and for 
efficient aminoacylation by LeuRS (Figure 2 and Table 1). This raises 
the possibility that LeuRS contacts the acceptor stem helix in a base-
specific manner. Perhaps subtle differences in the tertiary structures of 
the type II and type I variants resulted in different orientations of the 
acceptor stems in the LeuRS active site allowing the contributions of 
these nucleotides to aminoacy lation by LeuRS to be revealed. 
Interestingly we have observed a similar phenomenon in our study of 
tRNASer identity. Changes to the conserved acceptor base-pair, R4-Y69 
were deleterious in impaired tRNASer backgrounds, e.g. in minihelices 
or in tRNAs lacking the extra stem loop but the same changes had little 
effect in full length tRNA Ser (65). A contribution of this base pair to 
recognition by SerRS is consistent with specific RNA-protein 
interactions in this region seen in the refined structure of the 
homologous T. thermophilus tRNASecserRS complex (28). In light of 
the results for the serine system, and the observed "body specific" effects 
of the acceptor stem sequence on aminoacylation by LeuRS, it seems 
possible that LeuRS does in fact recognize the leucine specific bases in 
the acceptor stem. 
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Figure 1. Representation on a typical cloverleaf secondary structure of 
the residues absolutely conserved among the fiveE.coli tRNALeu species 
and the one coded by bacteriophage T4. The indicated nucleotides are 
divided in three different classes: 1) residues invariant among all tRNAs 
(letters in bold characters); 2) residues conserved only among tRNALeu 
(in outlined letters); 3) residues conserved among tRNALeu that differ 
from tRNASercGA ( shaded outlined letters). G21 is not conserved in 
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Figure 2 Sequences of STL variants. Efficiencies and identities were 
determined as described in the materials and methods section. LeuRS 
specificity changes indicate the level of decrease in Keat/KM relative to 
that of a T7-t:ranscribed wild type tRNA. See Table 1 and Materials and 
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Figure 3 Aminoacylation plateau levels were used to assess whether a 
variant tRNA maintained a tRNA-like structure, and was functionally 
active. Only variant transcripts that could be fully charged by at least 
one of the three aaRS were considered for aminoacylation kinetic studies 
(see Table 1). All reactions were peiformed at 1 µM tRNA and 2 µM 
aaRS under the conditions described in Materials and Methods. 
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Figure 4 Sequences of tRNASer and tRNALeu amber suppressors and 
extra-loop replacement variants. Suppression efficiencies and the amino 
acid identities were determined by (Normanly et al. , l 986a; Normanly et 
al. , 1992). In the Normanly et al. identity experiments tRNA Leu~ had 
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Figure 5 (a) tRNASTL9, a tRNASer variant with the minimal changes 
that confer tRNALeu identity. (b) The tRNASTL9 variants STL12 and 
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Table 1 Kinetic parameters for the aminoacylation of tRNA variants 
by LeuRS and SerRS of the tRNA studied. 
The kinetic parameters for tRNALeuuAA, CUA, UUU, STL2, STL3, 
STL 7, and STL9 were determined using at least five RNA concentrations 
ranging from 0.2 µM to 1.6 µM at a LeuRS concentration of 0.62 nM. 
The kinetic parameters for tRNASer, and tRNA~Ser were determined 
using RNA and SerRS concentrations identical to the conditions 
described elsewhere (Sampson & Saks, 1993). The individual kinetic 
parameters for these substrates were calculated from Eadie-Hofstee plots 
using the program ENZYME KINETICS (dogStar software/Indiana 
Univ.) . Individual kinetic parameters could not be obtained for the 
aminoacylation of Leu~CUA, STL8, and STL6 by LeuRS, and for the 
aminoacylation of STL5, STL7 and STL8 by SerRS. VO/[S] was 
assumed to reflect Keat/Km since the measured initial rates of 
aminoacylation were essentially proportional to RNA concentration 
indicating that the RNA concentrations were below Km and the reaction 
was first order. Initial rates for all substrates were calculated from a 
linear least square regression using five time points whose correlation 
coefficients were all 0.98 or greater. 
n.d.= not determined. 
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Leu RS Ser RS 
tRNA KM Keat Keat/KM Loss of KcatlKM Loss of 
Substrate (µM) (sec-1) (M-1.sec-1) Specificity (M-1.sec-1) Specificity 
TILEUUAA 0.21 3.2 1.5x107 (1.0) n.d. n.d. 
Native Leu 
UAA 0.23 2.7 l.2xl07 1.3 n.d. n.d. 
LEU CUA 0.22 0.70 3.3xl06 4.6 n.d. n.d. 
LEU UUU 0.26 2.6 l.Ox107 1.5 n.d. n.d. 
LEUt-.CUA n.m. n.m. 7.6x104 200 n.d. n.d. 
STL2 1.1 2.6 2.4x1Q6 6.3 n.m. >8300 
STL8 n.m. n.m. 1.3x1Q5 120 8x1Q2 8300 
STL7 0.65 1.2 l.8x106 8.4 2xl03 3300 
STL3 3.5 2.3 6.4xl05 23 n.m. >8300 
STL5 n.m. n.m. n.m. > 13,000 2.15x1Q3 3100 
STL6 n.m. n.m. 5. lx1Q3 3000 n.m. >8300 
STL9 0.93 1.7 l.8x1Q6 8.4 2.9xl03 2300 
SER n.m. n.m. n.m. >13,000 6.6x1Q6 ( 1.0) 
SER~ n.m. n.m. n.m. >13,000 1.45x 1Q3 4600 
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